MondegarAI
Logos Global Management LP

Q4 2024 · 13F-HR

Logos Global Management LPholdings as filed

Filed 2025-02-14 · accession 0001172661-25-001041

$854.6M
Reported value
47
Positions
2024-12-31
Period end
View analyzed profile →PRO

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
45166A102IDYAIDEAYA BIOSCIENCES INC$77.1M9.02%3,000,000CommonSOLE
47103J105JANXJANUX THERAPEUTICS INC$66.9M7.83%1,250,000CommonSOLE
76155X100RVMDREVOLUTION MEDICINES INC$63.4M7.42%1,450,000CommonSOLE
23282W605CYTKCYTOKINETICS INC$42.3M4.95%900,000CommonSOLE
92337R101VERAVERA THERAPEUTICS INC$37.0M4.33%875,000CommonSOLE
09075V102BNTXBIONTECH SE$34.2M4.00%300,000CommonSOLE
N5749R1002GHMERUS N V$31.5M3.69%750,000CommonSOLE
29479A108ERASERASCA INC$31.4M3.67%12,500,000CommonSOLE
457669307INSMINSMED INC$31.1M3.64%450,000CommonSOLE
67576A100OCULOCULAR THERAPEUTIX INC$29.9M3.50%3,500,000CommonSOLE
64125C109NBIXNEUROCRINE BIOSCIENCES INC$27.3M3.19%200,000CommonSOLE
25056L103DSGNDESIGN THERAPEUTICS INC$26.0M3.04%4,217,627CommonSOLE
92243G108PCVXVAXCYTE INC$24.6M2.87%300,000CommonSOLE
00973Y108AKROAKERO THERAPEUTICS INC$22.3M2.60%800,000CommonSOLE
G50871105JAZZJAZZ PHARMACEUTICALS PLC$21.6M2.52%175,000CommonSOLE
86366E106GPCRSTRUCTURE THERAPEUTICS INC$19.0M2.22%700,000CommonSOLE
68062P106OLMAOLEMA PHARMACEUTICALS INC$18.7M2.19%3,208,875CommonSOLE
09627Y1092655787DBLUEPRINT MEDICINES CORP$17.4M2.04%200,000CommonSOLE
89422G107TVTXTRAVERE THERAPEUTICS INC$17.4M2.04%1,000,000CommonSOLE
03753U106APLSUSDAPELLIS PHARMACEUTICALS INC$16.0M1.87%500,000CommonSOLE
834203309SLNOSOLENO THERAPEUTICS INC$15.7M1.84%350,000CommonSOLE
G01767105ALKSALKERMES PLC$14.4M1.68%500,000CommonSOLE
03770N101APGEAPOGEE THERAPEUTICS INC$13.6M1.59%300,000CommonSOLE
04335A105ARVNARVINAS INC$13.4M1.57%700,000CommonSOLE
03589W102ANNXANNEXON INC$13.1M1.53%2,550,000CommonSOLE
254604101IRONDISC MEDICINE INC$12.7M1.48%200,000CommonSOLE
00773J202SYRESPYRE THERAPEUTICS INC$11.6M1.36%500,000CommonSOLE
28036F105EWTXEDGEWISE THERAPEUTICS INC$10.7M1.25%400,000CommonSOLE
26818M108DYNDYNE THERAPEUTICS INC$10.6M1.24%450,000CommonSOLE
729139105PLRXPLIANT THERAPEUTICS INC$9.9M1.16%750,000CommonSOLE
10919W405DRUGBRIGHT MINDS BIOSCIENCES INC$8.8M1.03%245,000CommonSOLE
984241109YMABUSDY-MABS THERAPEUTICS INC$7.8M0.92%1,000,000CommonSOLE
45258J102IMVTIMMUNOVANT INC$7.4M0.87%300,000CommonSOLE
374163103GERNGERON CORP$7.1M0.83%2,000,000CommonSOLE
00461U105ACRSACLARIS THERAPEUTICS INC$5.5M0.64%2,222,222CommonSOLE
89532M101TRVITREVI THERAPEUTICS INC$5.2M0.60%1,250,000CommonSOLE
04635X102CATBUSDASTRIA THERAPEUTICS INC$4.5M0.52%500,000CommonSOLE
90466Y103UNICYCIVE THERAPEUTICS INC$4.0M0.47%5,078,927CommonSOLE
008064107AEROVATE THERAPEUTICS INC$3.7M0.43%1,400,000CommonSOLE
75383L102RAPPRAPPORT THERAPEUTICS INC$3.7M0.43%208,910CommonSOLE
002120202ATYRATYR PHARMA INC$3.6M0.42%1,000,000CommonSOLE
01671P100ALLKGUSDALLAKOS INC$3.5M0.41%2,900,000CommonSOLE
29337E102ELVNENLIVEN THERAPEUTICS INC$3.1M0.37%140,000CommonSOLE
81734D104SEPNSEPTERNA INC$3.1M0.36%134,202CommonSOLE
04317A107ARTVARTIVA BIOTHERAPEUTICS INC$1.5M0.17%145,089CommonSOLE
38000Q102GLYCEURGLYCOMIMETICS INC$1.3M0.16%5,400,000CommonSOLE
67080N119NUVB/WSNUVATION BIO INC$15,3330.00%66,666CommonSOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.